CER Daily Newsfeed

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One

(7/21, Sally Pipes, Forbes.com) comments “...The Incubate Coalition's Life Sciences Investment Tracker shows that drug companies have discontinued more than 50 research programs and canceled 26 drug projects since the passage of the IRA. And there's evidence that companies have been curtailing their research into orphan drugs, in particular. According to the National Pharmaceutical Council, ‘the percentage of drugs with a first orphan designation that later received a second designation decreased by 48.0%’ after the [IRA] passed. That's especially shocking considering that, over the four years prior to the passage of the bill, the number of orphan drugs that received a second indication had been steadily increasing.” Full

Study Reveals Comparative Effectiveness of Dietary Interventions for Type 2 Diabetes and Obesity Management

(7/21, Kennedy Ferruggia, The American Journal of Managed Care) reports “Various dietary approaches, including intermittent energy restriction (IER), time-restricted eating (TRE), and continuous energy restriction (CER), are all effective in improving blood sugar levels and promoting weight loss in individuals with type 2 diabetes (T2D) and obesity. The study authors, who presented their findings at the Endocrine Society’s 2025 annual meeting, noted that the current research is the first to compare the effects of 3 different dietary interventions.” Full

Video: How New Policies are Impacting Market Sustainability

(7/21, Ed Schoonveld, Edward Ahn, Shana Gunderson Hua, PharmD, Rob Philo, PharmExec) “...Key discussion topics include: The potential impact of MFN pricing on US drug costs and the current market. Why pricing transparency and value justification are increasingly essential for pharmaceutical companies. The role of scenario planning and value proposition refinement in navigating regulatory uncertainty.” View Video

Industry Perspectives on the Evolving Regulatory Landscape for Pragmatic Trials

(7/21, The Evidence Base) reports “...At the SCOPE Summit 2025, a panel discussion on ‘Regulatory Initiatives to Enable Pragmatic Trials’ brought together leading voices from across the industry. In this interview, Gracy Crane (Roche Products Ltd), Melodi McNeil (AbbVie), Henry Wei (Regeneron), Stephanie Derbyshire (Roche), Kevin Bugin (Amgen), and Meghana Chalasani (CDER, US FDA) share their perspectives on the evolving regulatory landscape and the opportunities to leverage pragmatic trials across a medicine’s lifecycle.” Full

Health Cuts Would Result in Fewer Drugs for Americans, Budget Office Reports

(7/18, Benjamin Mueller and Christina Jewett, The New York Times) reports “...The budget office also assessed a hypothetical scenario in which staffing reductions at the F.D.A. would delay the review of new drugs by nine months. Such delays would prevent 23 additional drugs from becoming available in that time period, according to the analysis.” Subscription Required